Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial.
Saved in:
| Title: | Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial. |
|---|---|
| Authors: | Martinon-Torres F; Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.; Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario and University of Santiago de Compostela (USC), Santiago de Compostela, Spain., Lamberth E; Pfizer Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USA., Natalini Martinez S; Vaccine Research Department, Instituto de Investigación Sanitaria HM, Madrid, Spain., Salamanca de la Cueva I; Unidad de Investigación, Grupo IHP (Instituto Hispalense de Pediatría), Sevilla, Spain., Zolotas L; Pfizer Vaccine Research and Development, Pfizer Ltd, Marlow, UK., Oladipupo I; Pfizer Vaccine Clinical Research and Development, Pfizer Inc, Pearl River, NY, USA., Maguire JD; Vaccine Research Department, Instituto de Investigación Sanitaria HM, Madrid, Spain., Trammel J; Vaccine Research Department, Instituto de Investigación Sanitaria HM, Madrid, Spain., O'Neill R; Pfizer Vaccine Clinical Research and Development, Pfizer Inc, Pearl River, NY, USA., Liberator PA; Pfizer Vaccine Clinical Research and Development, Pfizer Inc, Pearl River, NY, USA., Peyrani P; Pfizer Global Medical Affairs, Vaccines and Antivirals, Pfizer Inc, Collegeville, PA, USA., Jodar L; Pfizer Global Medical Affairs, Vaccines and Antivirals, Pfizer Inc, Collegeville, PA, USA., Gruber WC; Pfizer Vaccine Clinical Research and Development, Pfizer Inc, Pearl River, NY, USA., Anderson AS; Pfizer Vaccine Clinical Research and Development, Pfizer Inc, Pearl River, NY, USA., Beeslaar J; Pfizer Vaccine Research and Development, Pfizer Ltd, Marlow, UK. |
| Source: | Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2463194. Date of Electronic Publication: 2025 Feb 24. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2164-554X |
|---|---|
| DOI: | 10.1080/21645515.2025.2463194 |
